Beacon Financial Group Trims Stock Holdings in Sanofi (NASDAQ:SNY)

Beacon Financial Group reduced its holdings in Sanofi (NASDAQ:SNY) by 7.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,176 shares of the company’s stock after selling 1,133 shares during the quarter. Beacon Financial Group’s holdings in Sanofi were worth $684,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in SNY. AQR Capital Management LLC acquired a new position in Sanofi in the second quarter valued at $344,000. Koshinski Asset Management Inc. acquired a new position in Sanofi in the third quarter valued at $211,000. Creative Planning increased its stake in Sanofi by 18.0% in the third quarter. Creative Planning now owns 220,763 shares of the company’s stock valued at $12,723,000 after purchasing an additional 33,728 shares during the last quarter. Regatta Capital Group LLC increased its stake in Sanofi by 1.7% in the third quarter. Regatta Capital Group LLC now owns 16,611 shares of the company’s stock valued at $957,000 after purchasing an additional 274 shares during the last quarter. Finally, Asset Dedication LLC increased its stake in Sanofi by 284.1% in the third quarter. Asset Dedication LLC now owns 3,902 shares of the company’s stock valued at $225,000 after purchasing an additional 2,886 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $54.56 on Thursday. The firm has a market capitalization of $138.46 billion, a PE ratio of 21.91, a P/E/G ratio of 0.99 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74. The business has a 50-day moving average of $50.07 and a two-hundred day moving average of $52.41. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. As a group, research analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Wall Street Analyst Weigh In

SNY has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.